Medroxyprogesterone Acetate

What it is and how it works

Mechanism of Action Medroxyprogesterone acetate injectable suspension (medroxyprogesterone acetate [MPA]) inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect.

Indications

Medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use : The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate . Medroxyprogesterone acetate injectable suspension is a progestin indicated for use by females of reproductive potential to prevent pregnancy. Limitations of Use : The use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. ( 1 , 5.1 )

Dosage and administration (summary)

The recommended dose is 150 mg of medroxyprogesterone acetate injectable suspension every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle. Prevention of Pregnancy Both the 1 mL vial and the 1 mL prefilled syringe of medroxyprogesterone acetate injectable suspension should be vigorously shaken just before use to ensure that the dose being administered represents a uniform suspension.

Contraindications

The use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: Active thrombophlebitis, or current or history of thromboembolic disorders, or cerebral vascular disease . Known or suspected malignancy of breast . Known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients . Significant liver disease . Undiagnosed vaginal bleeding .

Warnings and precautions

Thromboembolic Disorders: Discontinue medroxyprogesterone acetate injectable suspension in patients who develop thrombosis. Cancer Risks: Monitor women with a strong family history of breast cancer carefully. Meningioma: Discontinue medroxyprogesterone acetate injectable suspension if meningioma is diagnosed. Monitor patients for signs and symptoms of meningioma. Ectopic Pregnancy: Consider ectopic pregnancy if a woman using medroxyprogesterone acetate injectable suspension becomes pregnant or complains of severe abdominal pain.

Pregnancy

Pregnancy Risk Summary There is no use for contraception in pregnancy; therefore, medroxyprogesterone acetate injectable suspension should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) followi…

Storage and supply

Medroxyprogesterone acetate sterile suspension, 150 mg/mL Medroxyprogesterone acetate injectable suspension, USP is a sterile, white to off white suspension and is supplied in the following package configurations: 150 mg per mL: 1 mL Single-Dose Vial Packaged Individually NDC 55150-329-01 1 mL Single-Dose Vials in a Carton of 25 NDC 55150-329-25 Vi…

Source: Medroxyprogesterone Acetate (Medroxyprogesterone Acetate) — US FDA prescribing information, 2026-01-08, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.